Eloxx Q2 net loss $10.6M; cash $30M; CF topline data expected Q3 2022

Eloxx Pharmaceuticals, Inc.

2022-Q2 EPS reported -$0.26

Q2 2022 net loss $10.6M ($0.12/sh) vs $36.1M ($0.54/sh) in Q2 2021; prior year included $22.7M Zikani acquisition expense.
Cash and equivalents $30.0M as of June 30, 2022; sufficient to fund operations into Q4 2023; in compliance with debt covenants.
CF Phase 2 expansion arms top-line results expected by end of Q3 2022; inhaled delivery IND on track for Q4 2022.
Alport syndrome proof-of-concept trial to start H2 2022 in up to 8 patients; topline results expected H1 2023.
ZKN-013 repeat study confirms potential in FAP model; IND for FAP expected H2 2023; RDEB IND on track for Q4 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.